VUMERITY (diroximel fumarate) delayed-release capsules, for oral use [prescribing information]. Cambridge: Biogen Inc.; 2023.

European Medicines Agency. Vumerity summary of product characteristics. 2022. https://www.ema.europa.eu/en/documents/product-information/vumerity-epar-product-information_en.pdf. Accessed 5 Jul 2022.

AUBAGIO (teriflunomide) tablets, for oral use [prescribing information]. Cambridge: Genzyme Corporation; 2022.

European Medicines Agency. Ponesimod summary of product characteristics. 2021. https://www.ema.europa.eu/en/documents/product-information/ponvory-epar-product-information_en.pdf. Accessed 5 Jul 2022.

PONVORY (ponesimod) tablets, for oral use [prescribing information]. Titusville: Janssen Pharmaceuticals; 2022.

European Medicines Agency. Teriflunomide summary of product characteristics. 2018. https://www.ema.europa.eu/en/documents/product-information/aubagio-epar-product-information_en.pdf. Accessed 5 Jul 2022.

Utz KS, Hoog J, Wentrup A, Berg S, Lammer A, Jainsch B, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Ther Adv Neurol Disord. 2014;7(6):263–75. https://doi.org/10.1177/1756285614555335.

Article  PubMed  PubMed Central  Google Scholar 

Jonker MF, Donkers B, Goossens LMA, Hoefman RJ, Jabbarian LJ, de Bekker-Grob EW, et al. Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options. Med Decis Making. 2020;40(2):198–211. https://doi.org/10.1177/0272989X19897944.

Article  PubMed  Google Scholar 

Cohan S, Kumar J, Arndorfer S, Zhu X, Zivkovic M, Tencer T. Comparative efficacy and safety of ozanimod and dimethyl fumarate for relapsing-remitting multiple sclerosis using matching-adjusted indirect comparison. CNS Drugs. 2021;35(7):795–804. https://doi.org/10.1007/s40263-021-00805-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan A, Cutter G, Fox RJ, Xiao J, Lewin JB, Edwards MR. Comparative effectiveness of delayed-release dimethyl fumarate versus glatiramer acetate in multiple sclerosis patients: results of a matching-adjusted indirect comparison. J Comp Eff Res. 2017;6(4):313–23. https://doi.org/10.2217/cer-2016-0085.

Article  PubMed  Google Scholar 

Fox RJ, Chan A, Zhang A, Xiao J, Levison D, Lewin JB, et al. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Curr Med Res Opin. 2017;33(2):175–83. https://doi.org/10.1080/03007995.2016.1248380.

Article  CAS  PubMed  Google Scholar 

Wundes A, Wray S, Gold R, Singer BA, Jasinska E, Ziemssen T, et al. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. Ther Adv Neurol Disord. 2021;14:1756286421993999. https://doi.org/10.1177/1756286421993999.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs. 2020;34(2):185–96. https://doi.org/10.1007/s40263-020-00700-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kappos L, Fox RJ, Burcklen M, Freedman MS, Havrdova EK, Hennessy B, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol. 2021;78(5):558–67. https://doi.org/10.1001/jamaneurol.2021.0405.

Article  PubMed  Google Scholar 

Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, et al. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler. 2020;26(13):1729–39. https://doi.org/10.1177/1352458519881761.

Article  CAS  PubMed  Google Scholar 

Wray S, Then Bergh F, Wundes A, Arnold DL, Drulovic J, Jasinska E, et al. Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase 3 EVOLVE-MS-1 study. Adv Ther. 2022;39(4):1810–31. https://doi.org/10.1007/s12325-022-02068-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kappos L, Burcklen M, Freedman MS, Fox R, Kubala Havrdová E, Hennessy B, et al. Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: phase 3 OPTIMUM study (P0071). Mult Scler J. 2020;26(3 Suppl):151–2. https://doi.org/10.1177/1352458520974937.

Article  Google Scholar 

Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–7. https://doi.org/10.1016/j.jval.2012.05.004.

Article  PubMed  Google Scholar 

Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–11. https://doi.org/10.1177/0272989X17725740.

Article  PubMed  Google Scholar 

Briggs FBS, Thompson NR, Conway DS. Prognostic factors of disability in relapsing remitting multiple sclerosis. Mult Scler Relat Disord. 2019;30:9–16. https://doi.org/10.1016/j.msard.2019.01.045.

Article  PubMed  Google Scholar 

Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010;133(Pt 7):1914–29. https://doi.org/10.1093/brain/awq118.

Article  PubMed  PubMed Central  Google Scholar 

Lanzillo R, Moccia M, Palladino R, Signoriello E, Carotenuto A, Maniscalco GT, et al. Clinical predictors of dimethyl fumarate response in multiple sclerosis: a real life multicentre study. Mult Scler Relat Disord. 2020;38:101871. https://doi.org/10.1016/j.msard.2019.101871.

Article  CAS  PubMed  Google Scholar 

Cellerino M, Boffa G, Lapucci C, Tazza F, Sbragia E, Mancuso E, et al. Predictors of ocrelizumab effectiveness in patients with multiple sclerosis. Neurotherapeutics. 2021;18(4):2579–88. https://doi.org/10.1007/s13311-021-01104-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577. https://doi.org/10.3389/fneur.2017.00577.

Article  PubMed  PubMed Central  Google Scholar 

Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics. 2015;33(6):537–49. https://doi.org/10.1007/s40273-015-0271-1.

Article  PubMed  Google Scholar 

Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935–45. https://doi.org/10.2165/11538370-000000000-00000.

Article  PubMed  Google Scholar 

Rothman K. Epidemiology: an introduction. New York: Oxford University Press, Inc.; 2012.

Google Scholar 

Lager B, Liseno J, Bozin I, England SM, Shankar SL, Mendoza JP, et al. Real-world analysis affirms the high persistence and adherence observed with diroximel fumarate in patients with multiple sclerosis. Neurol Ther. 2023;12(1):145–59. https://doi.org/10.1007/s40120-022-00413-0.

Article  PubMed  Google Scholar 

Hersh CM, Love TE, Bandyopadhyay A, Cohn S, Hara-Cleaver C, Bermel RA, et al. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Mult Scler J Exp Transl Clin. 2017;3(3):2055217317715485. https://doi.org/10.1177/2055217317715485.

Article  PubMed  PubMed Central  Google Scholar 

Laplaud DA, Casey R, Barbin L, Debouverie M, De Seze J, Brassat D, et al. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019;93(7):e635–46. https://doi.org/10.1212/WNL.0000000000007938.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braune S, Grimm S, van Hovell P, Freudensprung U, Pellegrini F, Hyde R, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol. 2018;265(12):2980–92. https://doi.org/10.1007/s00415-018-9083-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buron MD, Chalmer TA, Sellebjerg F, Frederiksen J, Gora MK, Illes Z, et al. Comparative effectiveness of teriflunomide and dimethyl fumarate: a nationwide cohort study. Neurology. 2019;92(16):e1811–20. https://doi.org/10.1212/WNL.0000000000007314.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conde S, Moisset X, Pereira B, Zuel M, Colamarino R, Maillet-Vioud M, et al. Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study. Eur J Neurol. 2019;26(3):460–7. https://doi.org/10.1111/ene.13839.

Article  CAS  PubMed  Google Scholar 

Bosco-Levy P, Debouverie M, Brochet B, Guillemin F, Louapre C, Maillart E, et al. Comparative effectiveness of dimethyl fumarate in multiple sclerosis. Br J Clin Pharmacol. 2022;88(3):1268–78. https://doi.org/10.1111/bcp.15071.

Article  CAS  PubMed  Google Scholar 

Bose D, Ravi R, Maurya M, Pushparajan L, Konwar M. Impact of disease-modifying therapies on MRI outcomes in patients with relapsing -remitting multiple sclerosis: a systematic review and network meta-analysis. Mult Scler Relat Disord. 2022;61:103760. https://doi.org/10.1016/j.msard.2022.103760.

Article  PubMed  Google Scholar 

Li H, Hu F, Zhang Y, Li K. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol. 2020;267(12):3489–98. https://doi.org/10.1007/s00415-019-09395-w.

Article  PubMed  Google Scholar 

Lucchetta RC, Tonin FS, Borba HHL, Leonart LP, Ferreira VL, Bonetti AF, et al. Disease-modifying therapies for relapsing-remitting multiple sclerosis: a network meta-analysis. CNS Drugs. 2018;32(9):813–26. https://doi.org/10.1007/s40263-018-0541-5.

Article  PubMed  Google Scholar 

Swallow E, Pham T, Patterson-Lomba O, Yin L, Gomez-Lievano A, Liu J, et al. Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: a matching-adjusted indirect comparison. Mult Scler Relat Disord. 2023;71:104551. https://doi.org/10.1016/j.msard.2023.104551.

Article  CAS  PubMed  Google Scholar